Delsitech

The industry leader in biodegradable silica-based controlled release of small molecule medications, biopharmaceuticals, and viral vectors is Delsitech which is one of the largest biotech company in Finland. The Biomaterial Research Group at the University of Turku and Ko Akademi University in Turku, Finland, created the technology, which is wholly owned and patented by DelSiTech.

Delsitech seeks to lessen the negative side effects of generic medications while increasing their efficacy. The business can do this by encapsulating the active ingredient in a silica matrix that is designed to release the medication into the body at the specified time interval, which can be anything between one day and up to a year. Entecavir, a daily-prescribed antiviral medication for hepatitis B, is the focus of the main program. The medicine might now be administered every three months thanks to Delsitech's delivery system, which would assist patients stick to their treatment regimen. The business also makes its technologies available to associate drug developers.

Headquarters: Turku

Founded: 2001

Website: https://www.delsitech.com/